100% efficacy to ombitasvir/paritaprevir/ritonavir (± dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patients

被引：0
|
作者：
Sanai, F. M. [1 ,2 ]
Alghamdi, A. S. [3 ]
Afghani, A. [4 ]
Alswat, K. A. [5 ]
Aseeri, A. [6 ]
Babatin, M. A. [3 ]
机构：
[1] King Abdul Aziz Med City, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[2] King Saud Univ, Liver Dis Res Ctr, Riyadh, Saudi Arabia
[3] King Fahad Hosp, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[4] King Fahad Hosp, Dept Med, Gastroenterol Unit, Madinah Al Munawarrah, Saudi Arabia
[5] King Saud Univ, Liver Dis Res Ctr, Dept Med, Gastroenterol Unit, Riyadh, Saudi Arabia
[6] King Fahd Med City, Riyadh, Saudi Arabia
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30944-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-277
引用
收藏
页码：S312 / S312
页数：1
相关论文
共 50 条
  • [41] Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study
    Waked, Imam
    Esmat, Gamal
    Fouad, Rabab
    Allam, Naglaa
    Hassany, Mohamed
    Mohey, Mohammad
    Shiha, Gamal
    Soliman, Reham
    Qaqish, Roula B.
    Hall, Coleen
    Alami, Negar N.
    Kopecky-Bromberg, Sarah
    Mobashery, Niloufar
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (11) : 1739 - 1744
  • [42] Improved Hepatic Profile in Hepatitis C Virus (HCV) Genotype (GT) 4-Infected Egyptian Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-II)
    Waked, Imam
    Esmat, Gamal E.
    Omar, Rabab F.
    Allam, Naglaa A.
    Hassany, Mohamed
    Mohey, Mohamed
    Yosry, Ayman
    Shiha, Gamal
    Soliman, Reham
    Martinez, Marisol
    Qaqish, Roula B.
    Hall, Coleen
    Mobashery, Niloufar
    HEPATOLOGY, 2016, 64 : 481A - 482A
  • [43] Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection
    Johnson, Scott J.
    Parise, Helene
    Virabhak, Suchin
    Filipovic, Ivana
    Samp, Jennifer C.
    Misurski, Derek
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 983 - 994
  • [44] Impact of hepatoprotective medications on the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir plus /- ribavirin in hepatitis C virus genotype 1b-infected Asian patients with and without cirrhosis in the ONYX-I and -II studies
    Chuang, W. -L.
    Luo, Y.
    Heo, J.
    Wang, G. -Q.
    Yu, M. -L.
    Kim, Y. J.
    Xie, Q.
    Peng, C. -Y.
    Zhang, M.
    Huang, Y.
    Lu, W.
    Fredrick, L. M.
    Mobashery, N.
    Wei, L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S746 - S746
  • [45] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan
    Atsukawa, Masanori
    Tsubota, Akihito
    Toyoda, Hidenori
    Takaguchi, Koichi
    Nakamuta, Makoto
    Watanabe, Tsunamasa
    Tada, Toshifumi
    Tsutsui, Akemi
    Ikeda, Hiroki
    Abe, Hiroshi
    Kato, Keizo
    Uojima, Haruki
    Ikegami, Tadashi
    Asano, Toru
    Kondo, Chisa
    Koeda, Mai
    Okubo, Tomomi
    Arai, Taeang
    Iwashita-Nakagawa, Ai
    Itokawa, Norio
    Kumada, Takashi
    Iwakiri, Katsuhiko
    HEPATOLOGY RESEARCH, 2019, 49 (04) : 369 - 376
  • [46] GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis
    Poordad, Fred
    Sedghi, Shahriar
    Pockros, Paul J.
    Ravendhran, Natarajan
    Reindollar, Robert
    Lucey, Michael R.
    Epstein, Michael S.
    Bank, Leslie
    Bernstein, David E.
    Trinh, Roger
    Krishnan, Preethi
    Pilot-Matias, Tami
    Polepally, Akshanth R.
    Pothacamury, Rajvineeth K.
    Unnebrink, Kristina
    Martinez, Marisol
    Nelson, David R.
    HEPATOLOGY, 2016, 64 : 431A - 432A
  • [47] Comparison of efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin between Asian and western HCV GT1b-infected patients
    Wei, L.
    Luo, Y.
    Chuang, W. -L.
    Paik, S. W.
    Yu, M. -L.
    Fredrick, L. M.
    Campbell, A.
    Trinh, R.
    Enejosa, J.
    Shulman, N. S.
    Heo, J.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S531 - S532
  • [48] Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir combination with or without ribavirin in difficult-to-treat genotype 1 chronic hepatitis C patients in Hong Kong
    Chan, Henry L. Y.
    Tsang, Owen T. Y.
    Hui, Yee Tak
    Fung, James Y. Y.
    Lui, Grace C. Y.
    Lai, Ching Lung
    Lo, Angeline O. S.
    Chan, Kam Hon
    But, David Y. K.
    Lao, Wai Cheung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 378 - 378
  • [49] Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
    Smith, Michael A.
    Lim, Alice
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6083 - 6094
  • [50] Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function
    Sise, Meghan E.
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (02): : 191 - 193
12345